<DOC>
	<DOCNO>NCT00002665</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy bone marrow transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy without bone marrow transplantation treat patient acute lymphocytic leukemia .</brief_summary>
	<brief_title>SWOG-9400 Combination Chemotherapy With Without Bone Marrow Transplantation Treating Patients With Previously Untreated Acute Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate front line induction therapy daunorubicin , vincristine , prednisone , asparaginase sufficiently effective warrant phase III trial patient acute lymphocytic leukemia ( ALL ) . II . Assess toxicity regimen patient population . III . Assess disease free overall survival toxicity associate allogeneic bone marrow transplantation ALL patient first remission follow induction consolidation therapy . IV . Assess disease free overall survival toxicity associate sequential regimen mercaptopurine , methotrexate vincristine , doxorubicin , dexamethasone , cyclophosphamide , thioguanine , cytarabine ALL patient first remission ineligible allogeneic bone marrow transplantation . V. Evaluate prognostic significance cell surface immunophenotype , Philadelphia chromosome , polymerase chain reaction detect BCR/abl fusion patient population . OUTLINE : Patients stratify accord age ( 15 29 v 30 49 v 50 65 ) , performance status ( 0-1 v 2-3 ) , participate center , candidate allogeneic bone marrow transplantation ( yes v ) . Patients receive induction chemotherapy consist daunorubicin IV day 1-3 , vincristine IV day 1 , 8 , 15 , 22 , oral prednisone day 1-28 , asparaginase IV intramuscularly ( IM ) day 15-24 . Patients persistent leukemia day 21 , receive additional induction therapy consist daunorubicin IV day 22 23 , vincristine IV day 29 36 , oral prednisone continue day 42 . Patients CNS leukemia receive additional therapy begin day 1 induction chemotherapy consist methotrexate intrathecally ( IT ) intraventricularly twice weekly blast absent spinal fluid . Patients receive oral leucovorin calcium every 6 hour total 4 dos follow IT dose absence blood count recovery . Following absence spinal fluid blast , patient receive methotrexate IT intraventricularly weekly 4 week monthly 1 year . Patients also receive cranial radiotherapy consolidation therapy 5 day week 2.5 week . Patients A1 bone marrow receive consolidation therapy follow completion induction therapy blood count recovery . Patients receive consolidation therapy consist cyclophosphamide IV day 1 , 15 , 29 , cytarabine IV day 2-5 , 9-12 , 16-19 , 23-26 , oral mercaptopurine day 1-28 , methotrexate IT day 2 , 9 , 16 , 23 . Following completion consolidation therapy , patient eligible allogeneic bone marrow transplantation receive total body radiotherapy 3 time day day -7 , -6 , -5 , twice day -4 , eptoposide IV 4 hour day -3 . Patients undergo allogeneic bone marrow transplantation day 0 . Following completion consolidation therapy , patient ineligible allogeneic bone marrow transplantation receive maintenance therapy consist oral mercaptopurine day 1-63 , oral methotrexate day 1 , 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 . Patients receive subsequent course maintenance therapy blood count recover . Patients receive second course maintenance therapy consist vincristine IV day 1 , 8 , 15 , 22 , doxorubicin IV day 1 , 8 , 15 , 22 , oral dexamethasone day 1-28 . Patients receive third course consist cyclophosphamide IV day 1 , oral thioguanine day 1-14 , cytarabine IV day 3-6 10-13 . Patients receive fourth course consist oral mercaptopurine oral methotrexate daily 2 year . Patients follow monthly 6 month every 2 month thereafter . PROJECTED ACCRUAL : A total 25-50 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm acute lymphocytic leukemia FAB class L1L2 Mixed immunophenotypic marker cytochemical myeloid marker allow No nonHodgkin 's lymphoma No chronic myelogenous leukemia blast crisis Concurrent registration cytogenetics protocol SWOG9007 require PATIENT CHARACTERISTICS : Age : 15 65 Performance status : SWOG 03 Hematopoietic : Not specify Hepatic : Bilirubin great 2 time normal ( unless elevation due leukemia ) AST great 3 time normal ( unless elevation due leukemia ) No chronic liver disease Renal : Creatinine great 2 time normal Cardiovascular : Left ventricular ejection fraction least 50 % MUGA echocardiogram No symptomatic congestive heart failure No symptomatic coronary artery disease No cardiomyopathy No uncontrolled arrhythmia Other : Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No prior remission induction chemotherapy acute lymphocytic leukemia</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>L1 adult acute lymphoblastic leukemia</keyword>
	<keyword>L2 adult acute lymphoblastic leukemia</keyword>
	<keyword>L3 adult acute lymphoblastic leukemia</keyword>
	<keyword>neutropenia</keyword>
	<keyword>thrombocytopenia</keyword>
</DOC>